Abstract
To investigate the effects of losartan and enalapril on serum uric acid in hypertensive patients with metabolic syndrome, one hundred and twenty six newly diagnosed mild hypertensive patients, having markers of metabolic syndrome included in the study. The patients were divided into two groups. Group 1 (60 patients) was given losartan (50 mg/ day) and group 2 (66 patients) enalapril (20 mg/ day) for a duration of 2 months. A control group of seventy apparently healthy individuals were included. Metabolic syndrome was diagnosed according to diagnostic criteria of metabolic syndrome related to the American National Cholesterol Education Program-Adult Treatment Panel III. Serum uric acid levels were measured before and after drug administration. The results revealed a significant higher levels of uric acid were found in the hypertensive patients as compared with control group and a significant drop of uric acid was noted after treatment with losartan but not with enalapril. In conclusions: this study demonstrates significantly higher serum uric acid concentrations in hypertensive patients having markers of metabolic syndrome. Losartan but not enalapril therapy produced a significant fall in the serum uric acid level. Losartan can be useful therapeutic agent to control blood pressure and to reduce serum uric acid level in hypertensive patients having markers of metabolic syndrome and hyperuricaemia.
 Key words: Hypertension, metabolic syndrome, uric acid, losartan, enalapril.
Highlights
Some investigators have suggested that uric acid plays a causal role in the development of cardiovascular disease [1] whereas others have concluded that uric acid merely reflects other concomitant risk factors, such as hypertension, insulin resistance, obesity, or lipid abnormality [2]
The elevated Serum uric acid (SUA) levels encountered in individuals with MS may reflect a compensatory mechanism counteracting the increased oxidative stress associated with the MS [21].In the present study, only losartan causes a significant reduction of serum uric acid concentrations in patients with metabolic syndrome after 2 months of therapy
This aspect of losartan therapy might have therapeutic advantages by reducing the risk of elevated uric acid in patient with MS, since elevated serum uric acid levels in patient with MS is regarded as a risk factor for the development of CV diseases [26] and may ameliorate hyperuricemia induced by other drugs
Summary
Some investigators have suggested that uric acid plays a causal role in the development of cardiovascular disease [1] whereas others have concluded that uric acid merely reflects other concomitant risk factors, such as hypertension, insulin resistance, obesity, or lipid abnormality [2]. Elevated serum uric acid concentrations are found in healthy offspring of parents with coronary heart disease, indicating a possible causal relationship [3]. Johnson et al [5] reported that elevated uric acid level was observed in 40% to 60% of hypertensive subjects; hypertension was observed in 50% to 65% of subjects with gout. Johnson et al [6] reported that hyperuricemia was observed in 25% of treated hypertensive subjects, 50% of those without treatment, and 75% to 100% of those with malignant hypertension or renal dysfunction
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
